Cardiovascular and renal outcomes of dual combination therapies with glucagon-like peptide-1 receptor agonists and sodium-glucose transport protein 2 inhibitors: a systematic review and meta-analysis

A synthesis of trial sub-analyses and large real-world cohorts found that combining a GLP-1 receptor agonist with an SGLT2 inhibitor (and in some cases finerenone) protects the heart and kidneys more than either drug alone in type 2 diabetes.